Following a year which saw a 143% increase in launched biosimilars in the US, here are three reasons why payers will drive adoption further in 2021.
John Fox
Advertisement
Articles by John Fox
Advertisement
Latest Updated Articles
- 3 Reasons US Payers Will Make 2021 a Banner Year for Biosimilars
November 12th 2020
Advertisement
Advertisement
Trending on PharmExec
1
M&A Roundup: Lisata Therapeutics Acquires Marea Therapeutics, mAbxience Enters Collaboration with Sandoz
2
Pharmaceutical Executive Daily: FDA Approves Fayuvi
3
The Battle to Own the GLP-1 Patient Journey
4
FDA Approves Kerendia for Adults with Chronic Kidney Disease and Type 1 Diabetes
5